Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4562 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2ARALDH1A1CA2TSHR | |
| SCHEMBL445133 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2ARALDH1A1CA2TSHR | |
| SCHEMBL16106147 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2ARALDH1A1CA2TSHR | |
| SCHEMBL2909384 | 0.98 | AR (0.41) | SMN1; SMN2ARALDH1A1CA2TSHR | |
| SCHEMBL14831166 | 0.89 | TAAR1 (0.41) | ARALDH1A1KMT2AMEN1BRD4 | |
| SCHEMBL14831167 | 0.89 | TAAR1 (0.41) | ARALDH1A1KMT2AMEN1BRD4 | |
| SCHEMBL16363903 | 0.85 | KDM4E (0.37) | ARALDH1A1CYP19A1KMT2AMEN1 | |
| SCHEMBL4532571 | 0.82 | AR (0.41) | SMN1; SMN2ARTSHRCYP19A1BRD4 | |
| SCHEMBL28983077 | 0.82 | DGAT1 (0.48) | SMN1; SMN2ALDH1A1TSHRKMT2ALMNA | |
| SCHEMBL28983075 | 0.82 | DGAT1 (0.48) | SMN1; SMN2ALDH1A1TSHRKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313539-A1 | Alpha, Beta-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-10-09 | — | — | US | claimed |
| EP-4553069-A1 | ALPHA,ß-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-05-14 | — | — | EP | claimed |
| CN-118207195-A | Enzymatic preparation of (S) -4-phenyl-2-oxazolidinone and (S) -oxirane | 宁波酶赛生物工程有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117947523-A | Chiral organic-inorganic hybrid lead halide nonlinear frequency doubling crystal | 南开大学 | 2024-04-30 | — | — | CN | claimed |
| CN-114957335-B | Method for preparing chiral metal halide from achiral precursor through chiral induction | 南开大学 | 2024-04-05 | — | — | CN | claimed |
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| CN-117186150-A | Preparation method of LFA-1 inhibitor | 维眸生物科技（上海）有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-117038905-A | Composite manganese-based positive electrode material, preparation method thereof and lithium ion battery | 蜂巢能源科技股份有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-116283948-A | Synthesis method of ezetimibe intermediate | 江苏阿尔法药业股份有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-116265456-A | Synthesis method of posaconazole mother ring with high chiral purity | 苏州汉德创宏生化科技有限公司 | 2023-06-20 | — | — | CN | claimed |
| JP-2840452-B2 | — | — | 1998-12-24 | — | — | JP | claimed |
| US-5728827-A | Process for the synthesis of azetidinones | SCHERING CORPORATION (US) | 1998-03-17 | — | — | US | claimed |
| EP-0672687-B1 | Process for producing amino-functional cyclodextrin derivatives | CONSORTIUM ELEKTROCHEM IND (DE) | 1997-03-19 | — | — | EP | claimed |
| CN-1126989-A | Process for the synthesis of azetidinones | SCHERING CORP (US) | 1996-07-17 | — | — | CN | claimed |
| US-5536826-A | OXAZOLIDINONE OR DERIVATIVE | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1996-07-16 | — | — | US | claimed |
| EP-0707567-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 1996-04-24 | — | — | EP | claimed |
| EP-0672687-A1 | Process for producing amino-functional cyclodextrin derivatives | Consortium für elektrochemische Industrie GmbH (DE) | 1995-09-20 | — | — | EP | claimed |
| WO-1995001961-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 1995-01-19 | — | — | WO | claimed |
| EP-0378657-B1 | OXAZOLIDINONE PENETRATION ENHANCING COMPOUNDS | RAJADHYAKSHA VITHAL J (US) | 1994-02-02 | — | — | EP | claimed |
| US-4960771-A | TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS; DRUGS, SUNSCREENS, INSECT REPELLENTS, COSMETICS | LVMH MOET HENNESSY LOUIS VUITTON, INC. | 1990-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313539-A1 | Alpha, Beta-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | DEGS1, ACAD11, HADHA | SMN1; SMN2 1477/4885AR 1843/4885ALDH1A1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.